Novotech to present benefits of outsourcing clinical
March 14, 2005 by admin
Filed under Company News, Company News 2005
March 14, 2005 – Boston, MA — Novotech, Australia’s leading contract research organization (CRO), CEO Alek Safarian has been invited to present Australia’s outstanding clinical trials capabilities at the inaugural Sachs Bloomberg CRO Partnering Forum in Boston (March 15, 2005).
In the past three years, Novotech has worked with more than 15 U.S.-based pharmaceutical and biotech companies, as well as many major European pharmas.
Safarian said the Forum was specifically designed to present best practices on creating, managing and sustaining clinical outsourcing partnerships that enable more efficient and safe trials.
According to Forum organizers Sachs Bloomberg Associates: “The CRO Partnering Forum is designed to be one of the most highly transactional forums this year, drawing together leading CRO’s, pharmas and biotechs to present best practices on creating, managing and sustaining clinical outsourcing partnerships that enable more efficient and safe trials, as well as highlighting industry developments and providing a marketing platform aimed at the numerous pharma and biotech companies attending the North America Forum.”
Safarian said he would be presenting the key benefits offered by Australian CRO’s.
“Clinical research trials in Australia can begin in as little as 2-3 months from the initiation of the approval process and cost up to 30% less than comparable Western countries such as the U.S. and in Europe,” he said.
“Australian regulatory procedures were supportive of the clinical trial process, while the patient population was similar to the U.S in terms of lifestyle and disease characteristics, and responsive to participation in leading edge clinical trials.”
Alek Safarian, CEO Novotech will speak at:
March 15, 2005 at 15.50 -17.00
Panel Discussion: Global Outsourcing for International Trials
Moderator: Dr Peter Kalinka, Managing Director, Accelsiors Group
Editors Please Note: Novotech was recently asked to participate in a research effort by market intelligence firm Life Science Insights (LSI) in a global review of outsourcing trends called Key Trends to Watch in Contract Research for 2005. The Report has identified Australia as a key site for clinical trial outsourcing partnerships.
The Report is available. Click here
About Novotech – Unsurpassed Local Knowledge and Network:
Increasingly, U.S. companies are turning to Australia to expedite the pace, and reduce the cost, of clinical trials, while maintaining the high standard of research that U.S. authorities demand. A 2001 Ernst and Young benchmarking study found that clinical research costs may be as much as 30 percent lower in Australia than in the United States and Europe.
In addition, Australian regulatory procedures often enable a trial to begin in as little as 2-3 months from the initiation of the approval process. This compares favorably to usual timelines in major Western countries.
As the largest independent CRO in Australia, Novotech offers a level of flexibility and local knowledge that is virtually unmatched among other contract research organizations in the region. This has helped Novotech develop a strong client base in the United States and Europe.
Headquartered in Sydney, Novotech is focused on the Australian and New Zealand markets but has worldwide reach through the company’s subsidiary in the United Kingdom and through key external partnerships and strategic alliances in North America and other regions.
